natgillin/translations-raw huggingface dataset:
- Øvrige indholdsstoffer: polysorbat 80, ethanol vandfri (se afsnit 2) og citronsyre vandfri (til pHjustering) 
- The other ingredients are polysorbate 80, ethanol anhydrous (see section 2) and anhydrous citric acid (for pH adjustment).
Efter stratificering i henhold til antallet af positive lymfeknuder (1-3, 4+), blev 1491 patienter randomiseret til enten at få enten docetaxel 75 mg/m2 administreret en time efter doxorubicin 50 mg/m2 og cyclophosphamid 500 mg/m2 (TAC-arm), eller doxorubicin 50 mg/m2, fulgt af fluoruracil 500 mg/ m2 og cyclophosphamid 500 mg/m2 (FAC-arm). 
After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomised to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (FAC arm).
Vaskulære sygdomme: Venøse tromboemboliske tilfælde er sjældent rapporteret. 
Vascular disorders Venous thromboembolic events have rarely been reported.
Det er påvist, at docetaxel er både embryo-og føtotoksisk hos kaniner og rotter, samt at de nedsætter fertiliteten hos rotter. 
Docetaxel has been shown to be both embryotoxic and foetotoxic in rabbits and rats, and to reduce fertility in rats (see section 5.3).
Primær G-CSF-profylakse bør overvejes til patienter, som får adjuverende behandling med TAC for brystkræft for at nedsætte risikoen for kompliceret neutropeni (febril neutropeni, forlænget neutropeni eller neutropenisk infektion). 
Primary G-CSF prophylaxis should be considered in patients who receive adjuvant therapy with TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic infection).
Der er rapporter om tilfælde af væskeretention såsom perifert ødem og sjældnere pleura-og perikardieekssudat, ascites og vægtøgning. 
Fluid retention includes events such as peripheral oedema and less frequently pleural effusion, pericardial effusion, ascites and weight gain.
Patienter i behandling med TCF bør have profylaktisk G-CSF for at nedsætte risikoen for kompliceret neutropeni (febril neutropeni, prolongeret neutropeni eller neutropenisk infektion). 
Patients treated with TCF should receive prophylactic G-CSF to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic infection).
• Ved behandling af lungekræft kan DOCETAXEL KABI enten indgives alene eller i kombination med cisplatin. 
- For the treatment of lung cancer, DOCETAXEL KABI could be administered either alone or in combination with cisplatin.
DOCETAXEL KABI i kombination med capecitabin 
DOCETAXEL KABI in combination with capecitabine
Arytmi (ikke alvorlig) 
Arrhythmia (no severe)
Dette regime blev administreret hver 3. uge i 4 cyklusser. 
This regimen is administered every 3 weeks for 4 cycles.
Derfor er den anbefalede dosis docetaxel 75mg/m2 til de patienter, der har forhøjet leverfunktionstest (LFT), og LFT skal måles ved start og før hver behandlingscyklus (se pkt. 
Therefore, the recommended dose of docetaxel in those patients with elevated liver function test (LFTs) is 75 mg/m2 and LFTs should be measured at baseline and before each cycle (see section 4.2).
Citronsyre, vandfri (pH-justering) 
Anhydrous citric acid (pH adjustment)
o Bland infusionsposen- eller flasken manuelt med vippende bevægelser. 
• Mix the infusion bag or bottle manually using a rocking motion.
Fase I-studier har undersøgt docetaxels farmakokinetiske egenskaber hos kræftpatienter efter indgift af 20- 115 mg/m2. 
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20115 mg/m2 in phase I studies.
Dette regime administreres hver 3. uge i 3 cyklusser. 
This regimen is administered every 3 weeks for 3 cycles.
DOCETAXEL KABI i kombination med cisplatin og 5-fluoruracil er indiceret til indledende behandling af patienter med inoperable, lokale, fremskredne skællede celle-carcinoma i hoved og hals. 
DOCETAXEL KABI in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Patienter med en udgangsværdi for neutrofile granulocytter på < 1.500 celler/mm3. 
Patients with baseline neutrophil count of < 1,500 cells/mm3.
For cisplatin- og 5-fluoruracil-dosis justeringer: Se tilsvarende produktresumé. 
For cisplatin and 5-fluorouracil dose adjustments, see the corresponding summary of product characteristics.
I nogle tilfælde (hyppighed ikke kendt) er permanent hårtab observeret. 
In some cases (frequency not known)
Meget almindelige (kan forekomme hos flere end 1 ud af 10 patienter): 
Very common (may affect more than 1 in 10 people):
Hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion blev reduceret hos patienter der fik primær G- CSF-profylakse (se pkt. 
The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8).
Bivirkningerne for docetaxel kan blive mere alvorlige, når docetaxel gives i kombination med andre kemoterapeutiske midler. 
The severity of adverse events of docetaxel may be increased when docetaxel is given in combination with other chemotherapeutic agents.
Ventrikulær arytmi inklusive ventrikulær takykardi (undertiden dødelig) er rapporteret hos patienter behandlet med docetaxel i kombinationsregimer inklusive doxorubicin, 5-fluorouracil og/eller cyclofosfamid (se pkt. 
Ventricular arrhythmia including ventricular tachycardia (sometimes fatal) has been reported in patients treated with docetaxel in combination regimens including doxorubicin, 5-fluorouracil and/ or cyclophosphamide (see section 4.8).
Sjældne (kan forekomme hos op til 1 ud af 1.000 patienter): 
Rare (may affect up to 1 in 1,000 people):
DOCETAXEL KABI i kombination med cisplatin og 5-fluoruracil er indiceret til behandling af patienter med metastatisk gastrisk adenokarcinom, inklusive adenokarcinom i den gastrooesophageale forbindelse, som ikke tidligere har fået kemoterapi mod metastatisk sygdom. 
DOCETAXEL KABI in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
o Fra et mikrobiologisk synspunkt skal rekonstituering/fortynding ske under kontrollerede og aseptiske forhold, og lægemidlet skal anvendes straks. 
• From a microbiological point of view, reconstitution /dilution must take place in controlled and aseptic conditions and the infusion solution should be used immediately.
Stigningen i overlevelse set i armen med ugentlig docetaxel var ikke statistisk signifikant sammenlignet med mitxantron kontrol-armen. 
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Beskrivelse af udvalgte bivirkninger ved adjuverende behandling med DOCETAXEL KABI 75 mg/m² i kombination med doxorubicin og cyclophosphamid hos patienter med lymfeknude-positiv (TAX 316) og lymfeknude-negativ (GEICAM 9805) brystkræft 
Description of selected adverse reactions for adjuvant therapy with DOCETAXEL KABI 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
DOCETAXEL KABI i kombination med doxorubicin og cyclophosphamid: Adjuverende behandling 
DOCETAXEL KABI in combination with doxorubicin and cyclophosphamide: adjuvant therapy
• Induktionskemoterapi efterfulgt af strålebehandling (TAX 323) MedDRA Systemorganklasser 
• Induction chemotherapy followed by chemoradiotherapy (TAX 324) MedDRA system organ classes
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver ml koncentrat indeholder 20 mg docetaxel vandfri. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 20 mg docetaxel anhydrous.
Amenorré (G3/4: NA) 
Amenorrhoea (G3/4: NA)
Almene symptomer og reaktioner på administrationsstedet: Der er sjældne rapporter om radiation recall-fænomen. 
General disorders and administration site conditions Radiation recall phenomena have rarely been reported.
Efter tilsætning til infusionspose 
Once added to the infusion bag
Effekt af docetaxel i indledende behandling til patienter med inoperable, lokale fremskredne SCCHN (Hensigt at behandle-analyse) 
Efficacy of docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)
1218 patienter med inoperabel ikke-småcellet lungekræft stadium IIIB eller IV med KPS på 70 % eller mere og som ikke tidligere havde fået kemoterapi mod denne tilstand, blev i et fase III-studie randomiseret til enten docetaxel (T) 75 mg/m2 administreret som 1-times infusion umiddelbart efterfulgt af cisplatin (Cis) 75 mg/m2 administreret i løbet af 30-60 minutter hver 3. uge (TCis), docetaxel 75 mg/m2 som en 1-times infusion i kombination med carboplatin (AUC 6 mg/ml per min) administreret i løbet af 30-60 minutter hver 3. uge, vinorelbin (V) 25 mg/ m2 administreret i løbet af 6 til 10 minutter på dag 1, 8, 15, 22 efterfulgt af cisplatin 100 mg/m2 administreret på dag 1 af cyklusser gentaget hver 4. uge (VCis). 
In a phase III study, 1218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy for this condition, were randomised to either docetaxel (T) 75 mg/m2 as a 1 hour infusion immediately followed by cisplatin (Cis) 75 mg/m2 over 30-60 minutes every 3 weeks (TCis), docetaxel 75 mg/m2 as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml.min) over 30-60 minutes every 3 weeks, or vinorelbine (V) 25 mg/m2 administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m2 administered on day 1 of cycles repeated every 4 weeks (VCis).
Neutropeni (G3/4: 32 %); 
Neutropenia (G3/4: 32%);
Forekomsten af tilbagefald ved 10 år var reduceret hos de patienter, som fik TAC, sammenlignet med dem, som fik FAC (henholdsvis 39 % versus 45 %). 
Incidence of relapses at 10 years was reduced in patients receiving TAC compared to those who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6% (p = 0.0043).
Total overlevelse (Primær endepunkt) Median overlevelsestid (måneder) 
Median survival (months)
Din læge vil beregne din legemsoverflade i m2 
Your doctor will calculate your body surface area in square meters (m²) and will determine the dose you should receive.
Asteni (alvorlig: 12,4 %); Væskeretention (alvorlig: 0,8 %); smerter 
Asthenia (severe: 12.4%); Fluid retention (severe: 0.8%);Pain
Myelodysplastisk syndrom blev rapporteret hos 2 ud af 744 TAC-patienter (0,3 %) og hos 1 ud af 736 FAC-patienter (0,1 %). 
Myelodysplastic syndrome was reported in 2 of 744 TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%).
Øvre mavesmerter; Tør mund 
Abdominal pain upper; Dry mouth
Hos de patienter, der tidligere havde fået behandling med alkylerende stoffer uden effekt, blev docetaxel sammenlignet med doxorubicin (75 mg/m2 hver 3. uge). 
In alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m² every 3 weeks).
Meget almindelige bivirkninger 
Very common adverse reactions
Kvalme; diarré; opkastning; konstipation; stomatitis; dyspepsi; mavesmerter 
Nausea; Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia;
• For capecitabin dosis-justeringer, se capecitabins produktresumé. 
• For capecitabine dose modifications, see capecitabine summary of product characteristics.
Væskeretention (alvorlig: 6,5 %) Asteni (alvorlig: 11,2 %); smerter 
Fluid retention (severe: 6.5%); Asthenia (severe: 11.2%); Pain
• Ved behandling af metastatisk gastrisk kræft indgives DOCETAXEL KABI i kombination med cisplatin og 5-fluoruracil. 
- For the treatment of metastatic gastric cancer, DOCETAXEL KABI is administered in combination with cisplatin and 5-fluorouracil.
Den anbefalede dosis af docetaxel er 75 mg/m2 som en 1-times infusion, efterfulgt af cisplatin 75 mg/m2, som en 1-3-timers infusion (begge kun på dag 1), efterfulgt af 5-fluoruracil 750 mg/m2 pr. dag, givet som en 24-timers kontinuerlig infusion i 5 dage, med start efter endt cisplatin-infusion. 
The recommended dose of docetaxel is 75 mg/m2 as a 1-hour infusion, followed by cisplatin 75 mg/m2, as a 1- to 3- hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.
• 255 patienter, som fik docetaxel i kombination med capecitabin. 
• 255 patients who received docetaxel in combination with capecitabine.
Tabel over bivirkninger ved adjuverende behandling med DOCETAXEL KABI 75 mg/m² i kombination med doxorubicin og cyclophosphamid hos patienter med lymfeknude-positiv (TAX 316) og lymfeknudenegativ (GEICAM 9805) brystkræft - pooled data: 
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with DOCETAXEL KABI 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
TAC-behandlede patienter havde 32 % lavere risiko for tilbagefald sammenlignet med de patienter, der blev behandlet med FAC (hazard ratio = 0,68; 95 % CI (0,49-0,93); p = 0,01). 
TAC-treated patients had a 32% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.68, 95% CI (0.49-0.93), p = 0.01).
En multicenter, åben, randomiseret undersøgelse har evalueret sikkerhed og effekt af docetaxel til behandling af patienter med metastatisk gastrisk adenokarcinom, inklusive adenokarcinom af den gastrooesophagele forbindelse. 
A multi-centre, open-label, randomised study, was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease.
Graviditet, amning og frugtbarhed Spørg din læge til råds, før du tager nogen form for medicin. 
Ask your doctor for advice before being given any medicine.
Patienter i docetaxel-armen fik docetaxel (T) 75 mg/m2 efterfulgt af cisplatin (P) 75 mg/m2 efterfulgt af 5fluoruracil 750 mg/m2 daglig som en kontinuerlig infusion i 5 dage. 
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
Du eller dine pårørende kan også indberette bivirkninger via det nationale rapporteringssystem anført i Appendiks V 
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Pyrexi (G3/4: 1 %); 
Pyrexia (G3/4: 1%);
• Lungefibrose (ardannelse og fortykkelse i lungerne samt åndenød) 
• pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath).
DOCETAXEL KABI i kombination med doxorubicin 
DOCETAXEL KABI in combination with doxorubicin
Infektion (G3/4: 3,6 %) Neutropenisk infektion 
Infection (G3/4: 6.3%); Neutropenic infection
På den anden side viste AC-armen en hyppigere forekomst af alvorlig anæmi (15,8 % versus 8,5 %) end AT-armen og tillige en hyppigere forekomst af alvorlig hjertetoksicitet: Hjerteinsufficiens (3,8 % versus 2,8 %), total LVEF-nedsættelse > 20 % (13,1 % versus 6,1 %), total LVEF-nedsættelse > 30 % (6,2 % versus 1,1 %). 
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1% versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
• Næseblod 
• bleeding from the nose
95 %CI p-værdi 
95% CI p-value*
1 hætteglas med 180 mg/9 ml. 
1 vial with 180 mg/9 ml
Alopeci (G3/4: 4,0 %) 
Alopecia (G3/4: 4.0%)
Der foreligger ingen data for patienter med nedsat leverfunktion i kombinationsbehandling ved andre indikationer. 
No data are available in patients with hepatic impairment treated by docetaxel in combination in the other indications.
Nedsættelsen af risikoen for progression var 32,1 % og blev associeret med en signifikant længere TTP (p = 0,0004) til fordel for TCF-armen.Overlevelse i alt var også signifikant længere (p = 0,0201) til fordel for TCFarmen med en nedsættelse af risikoen for død på 22,7 %. 
The risk reduction of progression was 32.1% and was associated with a significantly longer TTP (p = 0.0004) in favour of the TCF arm.
Opbevaringsforhold efter fortynding af lægemidlet, se pkt. 
For storage conditions of the diluted medicinal product, see section 6.3.
I begge arme fik patienter med ER + og/eller PR+ tumorer 20 mg tamoxifen en gang daglig i op til 5 år efter den sidste kemoterapicyklus. 
In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours received tamoxifen 20 mg once a day for up to 5 years.
• Sløret syn pga. hævet nethinde (cystoidt makulaødem) 
• blurred vision due to swelling of the retina within the eye (cystoid macular oedema)
• Induktions kemoterapi efterfulgt af strålebehandling (TAX 323) Sikkerheden og effekten af docetaxel i den indledende behandling af patienter med pladecellecarcinom i hovedet og halsen (SCCHN) blev evalueret i en fase III, multicenter, åben, randomiseret undersøgelse (TAX323). 
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multi-centre, open-label, randomised study (TAX323).
Data fra et multicenter, åbent, randomiseret studium støtter anvendelsen af DOCETAXEL KABI som adjuverende behandling til patienter med operabel, lymfeknude-negativ brystkræft, der er egnede til kemoterapibehandling. 
Data from a multi-centre open-label randomisedtrial support the use of DOCETAXEL KABI for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy.
G3/4 Forhøjet bilirubin i blodet (< 2,5 %); 
G3/4 Blood bilirubin increased (< 2.5%);
I kombinationsbehandling med cisplatin og 5-fluoruracil til behandling af patienter med gastrisk adenokarcinom ekskluderede pivotalstudiet patienter med ALAT og/eller ASAT > 1,5 gange ULN associeret med alkalisk fosfatase > 2,5 x ULN, og bilirubin > 1 x ULN. 
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
Kardiotoksicitet 
Cardiac disorders
Ved den mediane opfølgningsperiode på 10 år og 5 måneder havde TAC-behandlede patienter en 9 % lavere risiko for død sammenlignet med FAC-behandlede patienter (hazard ratio = 0,91; 95 % CI (0,63-1,32)). 
At the median follow up time of 10 years and 5 months, TAC-treated patients had a 9% reduction in the risk of death compared to FAC-treated patients (hazard ratio = 0.91, 95% CI (0.63-1.32)).
Total overlevelse ved 10 år var også signifikant forøget med TAC i forhold til FAC (henholdsvis 76 % versus 69 %). 
Overall survival at 10 years was also significantly increased with TAC compared to FAC (76% versus 69%, respectively) i.e. an absolute reduction of the risk of death by 7% (p = 0.002).
Patienter i komparator-armen modtog cisplatin (P) 100 mg/m2 administreret som en 30 minutter til 3 timers intravenøs infusion på dag 1, efterfulgt af kontinuerlig intravenøs infusion af 5-fluoruracil(F) 1000 mg/m2/dag fra dag 1 til dag 5. 
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 5.
Ved den mediane opfølgningsperiode på 77 måneder blev der vist signifikant længere sygdoms-fri overlevelse (DFS) i TAC-armen sammenlignet med FAC-armen. 
At the median follow-up was 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
Neglesygdomme (alvorlig: 2,6 %) 
Nail disorders (severe: 2.6%)
Hazard ratio (95 %CI) **p-værdi n = 128 
Hazard ratio (95% CI) **p-value n = 128
Mængden af alkohol i dette lægemiddel og bivirkningerne ved lægemidlet kan forringe evnen til at køre bil eller betjene maskiner (se pkt. 
The amount of alcohol in this medicinal product and the side effects of the product may impair the ability to drive or use machines (see sections 4.4 and 4.8).
Effekt af docetaxel i indledende behandling til patienter med lokale fremskredne SCCHN (Hensigt at behandle-analyse) 
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-toTreat Analysis)
For cisplatin-dosisjustering, se tilsvarende produktresumé 
For cisplatin dose adjustments, see the corresponding summary of product characteristics.
I studiet GEICAM 9805 forekom perifer sensorisk neuropati under behandlingen og fortsatte ind i opfølgningsperioden hos 10 patienter (1,9 %) i TAC-armen og hos 4 patienter (0,8 %) i FAC-armen.Ved afslutningen af opfølgningsperioden (median opfølgningstid på 10 år og 5 måneder) blev det observeret, at perifer sensorisk neuropati fortsatte hos 3 patienter (0,6 %) i TAC-armen og hos 1 patient (0,2 %) i FAC-armen. 
In GEICAM 9805 study peripheral sensory neuropathy that started during the treatment period persisted into the follow-up period in 10 patients (1.9%) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), peripheral sensory neuropathy was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Data fra et randomiseret, kontrolleret, klinisk fase 3-multicenterstudie understøtter anvendelsen af capecitabin i kombination med docetaxel til behandling af patienter med lokal fremskreden eller metastatisk brystkræft hos hvem cytotoksisk kemoterapi med et anthracyklin, har været uden effekt. 
Data from one multi-centre, randomised, controlled phase III clinical study support the use of docetaxel in combination with capecitabine for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline.
Den anbefalede doxetaxel-dosis til adjuverende behandling af operabel lymfeknude-positiv og lymfeknude-negativ brystkræft er 75 mg/m2 hver 3. uge i 6 perioder, administreret 1 time efter doxorubicin 50 mg/m2 og cyclophosphamid 500 mg/m2 (TAC-regime) (se også: Dosisjustering under behandling). 
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment).
• Hudreaktioner på injektionsstedet, betændelse eller hævelse af venen (flebitis) 
• at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
Sådan skal du bruge DOCETAXEL KABI 
How to use DOCETAXEL KABI
• 258 patienter, som fik docetaxel i kombinationsbehandling med doxorubicin. 
• 258 patients who received docetaxel in combination with doxorubicin.
Neglesygdomme (alvorlig:0,8 %) 
Nail disorders (severe: 0.8%)
Hvert hætteglas af koncentrat indeholder 0,5 ml ethanol vandfri (395 mg). 
Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
Myalgi (alvorlig: 1,4 %) Artralgi 
Myalgia (severe: 1.4%)